Guggenheim Maintains Buy on Sagimet Biosciences, Lowers Price Target to $25
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27 to $25.
Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $27 to $25.